文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

成人COVID-19与非COVID急性呼吸窘迫综合征ICU患者使用超声心动图与对比剂气泡研究检测肺内与心内分流(COVID-Shunt研究):一项前瞻性观察性队列研究

Intrapulmonary and Intracardiac Shunts in Adult COVID-19 Versus Non-COVID Acute Respiratory Distress Syndrome ICU Patients Using Echocardiography and Contrast Bubble Studies (COVID-Shunt Study): A Prospective, Observational Cohort Study.
PubMed 文献 · Crit Care Med · 2023-03-27
一句话结论COVID-19 ARDS与非COVID ARDS的右向左分流发生率无差异(17.0% vs 22.7%,RD -5.7%,p=0.38);COVID-19组右向左分流与住院死亡率升高相关(54.8% vs 35.8%,RD 19.0%,p=0.05),但90天死亡率及回归调整后未持续。

该前瞻性观察性队列研究纳入加拿大埃德蒙顿4家三级医院的226例成人危重机械通气ICU患者(COVID-19 182例 vs 非COVID 42例),采用振荡生理盐水气泡研究联合经胸超声心动图/经颅多普勒±经食管超声心动图评估右向左分流。主要结局为分流频率及与住院死亡率的关系。COVID-19患者右向左分流频率为17.0%(31/182),非COVID为22.7%(10/44),分流率无差异(RD -5.7%,95%CI -18.4至7.0,p=0.38)。COVID-19组中,有右向左分流者住院死亡率高于无分流者(54.8% vs 35.8%;RD 19.0%,95%CI 0.1-37.9,p=0.05),但该差异在90天死亡率及逻辑回归调整后未持续。

要点

  • COVID-19 ARDS与非COVID ARDS的右向左分流发生率无差异:COVID-19组17.0%(31/182) vs 非COVID组22.7%(10/44),RD -5.7%(95%CI -18.4至7.0),p=0.38。
  • COVID-19组中,有右向左分流者住院死亡率高于无分流者:54.8% vs 35.8%,RD 19.0%(95%CI 0.1-37.9),p=0.05。
  • 上述住院死亡率差异在90天死亡率及逻辑回归调整后未持续。
  • 研究采用振荡生理盐水气泡研究联合经胸超声心动图/经颅多普勒±经食管超声心动图评估右向左分流。

适用人群与场景

  • 成人危重、机械通气、因COVID-19或非COVID收入ICU的患者,研究时间为2020年11月16日至2021年9月1日。

研究设计与关键结果

  • 研究类型为前瞻性观察性队列研究,纳入4家三级医院共226例患者(COVID-19 182例 vs 非COVID 42例),中位年龄58岁(IQR 47-67岁),APACHE II评分30分(IQR 21-36)。
  • COVID-19组右向左分流频率为17.0%(31/182),非COVID组为22.7%(10/44),分流率无差异(RD -5.7%,95%CI -18.4至7.0,p=0.38)。
  • COVID-19组中,有右向左分流者住院死亡率高于无分流者(54.8% vs 35.8%;RD 19.0%,95%CI 0.1-37.9,p=0.05)。
  • 该住院死亡率差异在90天死亡率及逻辑回归调整后未持续。

证据类型、等级与局限

  • 证据类型:前瞻性观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Studies have suggested intrapulmonary shunts may contribute to hypoxemia in COVID-19 acute respiratory distress syndrome (ARDS) with worse associated outcomes. We evaluated the presence of right-to-left (R-L) shunts in COVID-19 and non-COVID ARDS patients using a comprehensive hypoxemia workup for shunt etiology and associations with mortality.

DESIGN: Prospective, observational cohort study.

SETTING: Four tertiary hospitals in Edmonton, Alberta, Canada.

PATIENTS: Adult critically ill, mechanically ventilated, ICU patients admitted with COVID-19 or non-COVID (November 16, 2020, to September 1, 2021).

INTERVENTIONS: Agitated-saline bubble studies with transthoracic echocardiography/transcranial Doppler ± transesophageal echocardiography assessed for R-L shunts presence.

MEASUREMENTS AND MAIN RESULTS: Primary outcomes were shunt frequency and association with hospital mortality. Logistic regression analysis was used for adjustment. The study enrolled 226 patients (182 COVID-19 vs 42 non-COVID). Median age was 58 years (interquartile range [IQR], 47-67 yr) and Acute Physiology and Chronic Health Evaluation II scores of 30 (IQR, 21-36). In COVID-19 patients, the frequency of R-L shunt was 31 of 182 COVID patients (17.0%) versus 10 of 44 non-COVID patients (22.7%), with no difference detected in shunt rates (risk difference [RD], -5.7%; 95% CI, -18.4 to 7.0; p = 0.38). In the COVID-19 group, hospital mortality was higher for those with R-L shunt compared with those without (54.8% vs 35.8%; RD, 19.0%; 95% CI, 0.1-37.9; p = 0.05). This did not persist at 90-day mortality nor after adjustment with regression.

CONCLUSIONS: There was no evidence of increased R-L shunt rates in COVID-19 compared with non-COVID controls. R-L shunt was associated with increased in-hospital mortality for COVID-19 patients, but this did not persist at 90-day mortality or after adjusting using logistic regression.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lau VI, Mah GD, Wang X, et al. Intrapulmonary and Intracardiac Shunts in Adult COVID-19 Versus Non-COVID Acute Respiratory Distress Syndrome ICU Patients Using Echocardiography and Contrast Bubble Studies (COVID-Shunt Study): A Prospective, Observational Cohort Study. Crit Care Med. 2023. PMID: 36971440. doi:10.1097/CCM.0000000000005848

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。